Table 1.
Clinical and demographical characteristics of patients treated with high-dose immunoablative suppression followed by AHSCT
| RRMS (n = 28) | SPMS (n = 10) | Total series (n = 38) | |
|---|---|---|---|
| Sex (n, % females) | 20 (71.4) | 7 (70.0) | 27 (71.1) |
| Age at AHSCT (mean, SD) | 36.4 (9.1) | 37.5 (9.1) | 36.7 (9.1) |
| MS duration at AHSCT (mean, SD) | 10.0 (8.5) | 8.0 (4.4) | 9.5 (7.6) |
| Relapses at year 2 before AHSCT (mean, SD) | 0.89 (0.9) | 0.8 (1.1) | 0.8 (0.9) |
| Relapses in the year previous AHSCT (mean, SD)1 | 1.6 (0.9) | 1.3 (1.7) | 1.5 (1.1) |
| EDSS 2 years before AHCST (mean, SD)2 | 3.2 (1.2) | 5.1 (1.1) | 3.7 (1.4) |
| EDSS 1 year before AHSCT (mean, SD)3 | 3.8 (1.1) | 5.4 (0.8) | 4.3 (1.3) |
| Baseline EDSS (mean, SD)4 | 5.0 (1.3) | 6.0 (0.7) | 5.3 (1.2) |
| MRI | |||
| Number of Gd-enhanced lesions (mean, SD) | 2.2 (4.4) | 1.3 (2.3) | 2.0 (3.9) |
| Patients with Gd-enhanced lesions (n, %) | 17 (60.7) | 3 (33.3) | 20 (54.1) |
| Cerebrospinal fluid | |||
| Presence of oligoclonal G bands (n = 30) (n, %) | 21 (91.3) | 7 (100) | 28 (93.3) |
| Presence of oligoclonal M bands (n = 25) (n, %) | 9 (42.9) | 2 (50.0) | 11 (44.0) |
| Previous treatments, no. (%) | |||
| One treatment | 4 (14.2) | 2 (20.0) | 6 (15.7) |
| Two treatments | 7 (25.0) | 4 (40.0) | 11 (28.9) |
| Three treatments | 8 (28.5) | 1 (10.0) | 9 (23.8) |
| Four treatments | 3 (10.7) | 3 (30.0) | 6 (15.7) |
| Five treatments | 3 (10.7) | – | 3 (7.8) |
| Six treatments | 3 (10.7) | – | 3 (7.8) |
| Patients that received immunosuppressors | 24 (85.7) | 8 (80.0) | 32 (84.2) |
| Median number and range of treatments received | 3 (1–6) | 2 (1–4) | 3 (1–6) |
| Mean time on treatment previous AHSCT (SD), years | 4.9 (3.6) | 3.5 (2.5) | 4.5 (3.4) |
1 p = 0.04; 2 p = 0.001; 3 p = 0.001; 4 p = 0.02